Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Time of Day of Influenza Vaccine Administration in Adults Aged 60-85 Years
2024-513558-30-00Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of quadrivalent influenza vaccine, Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen and 23-valent pneumococcal polysaccharide vaccine in influenza and pneumococcal disease (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Increase in influenza vaccine strain-specific serum antibody titers. Started Aug 2024; status: completed.
02
Drugs
quadrivalent influenza vaccineInfluenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen23-valent pneumococcal polysaccharide vaccine
03
Conditions
influenzapneumococcal disease
Beyond the preview
Go deeper on 2024-513558-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513558-30-00.